Journal article 396 views 52 downloads
The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review
John P. H. Wilding 
,
Marc Evans,
Kevin Fernando,
Jose Luis Gorriz,
Ana Cebrian,
Jane Diggle,
Debbie Hicks,
June James,
Philip Newland-Jones,
Amar Ali,
Steve Bain ,
Andrea Da Porto,
Dipesh Patel,
Adie Viljoen,
David C. Wheeler,
Stefano Del Prato
,
Marc Evans,
Kevin Fernando,
Jose Luis Gorriz,
Ana Cebrian,
Jane Diggle,
Debbie Hicks,
June James,
Philip Newland-Jones,
Amar Ali,
Steve Bain ,
Andrea Da Porto,
Dipesh Patel,
Adie Viljoen,
David C. Wheeler,
Stefano Del Prato
Diabetes Therapy, Volume: 13, Issue: 5, Pages: 847 - 872
Swansea University Author:
Steve Bain
-
PDF | Version of Record
The Author(s) 2022. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Download (1.84MB)
DOI (Published version): 10.1007/s13300-022-01228-w
Abstract
Over recent years, the expanding evidence base for sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapies has revealed benefits beyond their glucose-lowering efficacy in the treatment of Type 2 diabetes mellitus (T2DM), resulting in their recognition as cardiorenal medicines. While SGLT2is cont...
| Published in: | Diabetes Therapy |
|---|---|
| ISSN: | 1869-6953 1869-6961 |
| Published: |
Springer Science and Business Media LLC
2022
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa59694 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| first_indexed |
2022-03-22T16:55:20Z |
|---|---|
| last_indexed |
2022-05-18T03:35:10Z |
| id |
cronfa59694 |
| recordtype |
SURis |
| fullrecord |
<?xml version="1.0"?><rfc1807><datestamp>2022-05-17T15:09:35.3343577</datestamp><bib-version>v2</bib-version><id>59694</id><entry>2022-03-22</entry><title>The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2022-03-22</date><deptcode>BMS</deptcode><abstract>Over recent years, the expanding evidence base for sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapies has revealed benefits beyond their glucose-lowering efficacy in the treatment of Type 2 diabetes mellitus (T2DM), resulting in their recognition as cardiorenal medicines. While SGLT2is continue to be recommended among the second-line therapies for the treatment of hyperglycaemia, their true value now extends to the prevention of debilitating and costly cardiovascular and renal events for high-risk individuals, with particular benefit shown in reducing major adverse cardiac events and heart failure (HF) and slowing the progression of chronic kidney disease. However, SGLT2i usage is still suboptimal among groups considered to be at greatest risk of cardiorenal complications. The ongoing coronavirus disease 2019 (COVID-19) pandemic has intensified financial pressures on healthcare systems, which may hamper further investment in newer effective medicines. Emerging evidence indicates that glycaemic control should be prioritised for people with T2DM in the era of COVID-19 and practical advice on the use of T2DM medications during periods of acute illness remains important, particularly for healthcare professionals working in primary care who face multiple competing priorities. This article provides the latest update from the Improving Diabetes Steering Committee, including perspectives on the value of SGLT2is as cost-effective therapies within the T2DM treatment paradigm, with particular focus on the latest published evidence relating to the prevention or slowing of cardiorenal complications. The implications for ongoing and future approaches to diabetes care are considered in the light of the continuing coronavirus pandemic, and relevant aspects of international treatment guidelines are highlighted with practical advice on the appropriate use of SGLT2is in commonly occurring T2DM clinical scenarios. The ‘SGLT2i Prescribing Tool for T2DM Management’, previously published by the Steering Committee, has been updated to reflect the latest evidence and is provided in the Supplementary Materials to help support clinicians delivering T2DM care.</abstract><type>Journal Article</type><journal>Diabetes Therapy</journal><volume>13</volume><journalNumber>5</journalNumber><paginationStart>847</paginationStart><paginationEnd>872</paginationEnd><publisher>Springer Science and Business Media LLC</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>1869-6953</issnPrint><issnElectronic>1869-6961</issnElectronic><keywords>SGLT2 inhibitors; Oral glucoselowering medicines; Type 2 diabetes mellitus; Prescribing tools; Heart failure; Chronic kidney disease; Diabetic kidney disease; Cardiovascular disease; Cardiovascular risk; Cardiorenal protection</keywords><publishedDay>1</publishedDay><publishedMonth>5</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-05-01</publishedDate><doi>10.1007/s13300-022-01228-w</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>The Improving Diabetes Steering Committee is supported by an educational grant from Napp Pharmaceuticals Limited and Mundipharma Research Limited. Napp has reviewed this document for factual accuracy only. Sponsorship and the journal’s Rapid Service Fee for this study were funded by Mundipharma Research Limited.</funders><lastEdited>2022-05-17T15:09:35.3343577</lastEdited><Created>2022-03-22T16:54:19.9696295</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>John P. H.</firstname><surname>Wilding</surname><orcid>0000-0003-2839-8404</orcid><order>1</order></author><author><firstname>Marc</firstname><surname>Evans</surname><order>2</order></author><author><firstname>Kevin</firstname><surname>Fernando</surname><order>3</order></author><author><firstname>Jose Luis</firstname><surname>Gorriz</surname><order>4</order></author><author><firstname>Ana</firstname><surname>Cebrian</surname><order>5</order></author><author><firstname>Jane</firstname><surname>Diggle</surname><order>6</order></author><author><firstname>Debbie</firstname><surname>Hicks</surname><order>7</order></author><author><firstname>June</firstname><surname>James</surname><order>8</order></author><author><firstname>Philip</firstname><surname>Newland-Jones</surname><order>9</order></author><author><firstname>Amar</firstname><surname>Ali</surname><order>10</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>11</order></author><author><firstname>Andrea Da</firstname><surname>Porto</surname><order>12</order></author><author><firstname>Dipesh</firstname><surname>Patel</surname><order>13</order></author><author><firstname>Adie</firstname><surname>Viljoen</surname><order>14</order></author><author><firstname>David C.</firstname><surname>Wheeler</surname><order>15</order></author><author><firstname>Stefano Del</firstname><surname>Prato</surname><order>16</order></author></authors><documents><document><filename>59694__23912__1273a02d8e964210a9cb38cb35eb83a7.pdf</filename><originalFilename>59694.pdf</originalFilename><uploaded>2022-04-25T16:27:45.2842468</uploaded><type>Output</type><contentLength>1927610</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>The Author(s) 2022. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc/4.0/</licence></document></documents><OutputDurs/></rfc1807> |
| spelling |
2022-05-17T15:09:35.3343577 v2 59694 2022-03-22 The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2022-03-22 BMS Over recent years, the expanding evidence base for sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapies has revealed benefits beyond their glucose-lowering efficacy in the treatment of Type 2 diabetes mellitus (T2DM), resulting in their recognition as cardiorenal medicines. While SGLT2is continue to be recommended among the second-line therapies for the treatment of hyperglycaemia, their true value now extends to the prevention of debilitating and costly cardiovascular and renal events for high-risk individuals, with particular benefit shown in reducing major adverse cardiac events and heart failure (HF) and slowing the progression of chronic kidney disease. However, SGLT2i usage is still suboptimal among groups considered to be at greatest risk of cardiorenal complications. The ongoing coronavirus disease 2019 (COVID-19) pandemic has intensified financial pressures on healthcare systems, which may hamper further investment in newer effective medicines. Emerging evidence indicates that glycaemic control should be prioritised for people with T2DM in the era of COVID-19 and practical advice on the use of T2DM medications during periods of acute illness remains important, particularly for healthcare professionals working in primary care who face multiple competing priorities. This article provides the latest update from the Improving Diabetes Steering Committee, including perspectives on the value of SGLT2is as cost-effective therapies within the T2DM treatment paradigm, with particular focus on the latest published evidence relating to the prevention or slowing of cardiorenal complications. The implications for ongoing and future approaches to diabetes care are considered in the light of the continuing coronavirus pandemic, and relevant aspects of international treatment guidelines are highlighted with practical advice on the appropriate use of SGLT2is in commonly occurring T2DM clinical scenarios. The ‘SGLT2i Prescribing Tool for T2DM Management’, previously published by the Steering Committee, has been updated to reflect the latest evidence and is provided in the Supplementary Materials to help support clinicians delivering T2DM care. Journal Article Diabetes Therapy 13 5 847 872 Springer Science and Business Media LLC 1869-6953 1869-6961 SGLT2 inhibitors; Oral glucoselowering medicines; Type 2 diabetes mellitus; Prescribing tools; Heart failure; Chronic kidney disease; Diabetic kidney disease; Cardiovascular disease; Cardiovascular risk; Cardiorenal protection 1 5 2022 2022-05-01 10.1007/s13300-022-01228-w COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University The Improving Diabetes Steering Committee is supported by an educational grant from Napp Pharmaceuticals Limited and Mundipharma Research Limited. Napp has reviewed this document for factual accuracy only. Sponsorship and the journal’s Rapid Service Fee for this study were funded by Mundipharma Research Limited. 2022-05-17T15:09:35.3343577 2022-03-22T16:54:19.9696295 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine John P. H. Wilding 0000-0003-2839-8404 1 Marc Evans 2 Kevin Fernando 3 Jose Luis Gorriz 4 Ana Cebrian 5 Jane Diggle 6 Debbie Hicks 7 June James 8 Philip Newland-Jones 9 Amar Ali 10 Steve Bain 0000-0001-8519-4964 11 Andrea Da Porto 12 Dipesh Patel 13 Adie Viljoen 14 David C. Wheeler 15 Stefano Del Prato 16 59694__23912__1273a02d8e964210a9cb38cb35eb83a7.pdf 59694.pdf 2022-04-25T16:27:45.2842468 Output 1927610 application/pdf Version of Record true The Author(s) 2022. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License true eng http://creativecommons.org/licenses/by-nc/4.0/ |
| title |
The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review |
| spellingShingle |
The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review Steve Bain |
| title_short |
The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review |
| title_full |
The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review |
| title_fullStr |
The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review |
| title_full_unstemmed |
The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review |
| title_sort |
The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review |
| author_id_str_mv |
5399f4c6e6a70f3608a084ddb938511a |
| author_id_fullname_str_mv |
5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain |
| author |
Steve Bain |
| author2 |
John P. H. Wilding Marc Evans Kevin Fernando Jose Luis Gorriz Ana Cebrian Jane Diggle Debbie Hicks June James Philip Newland-Jones Amar Ali Steve Bain Andrea Da Porto Dipesh Patel Adie Viljoen David C. Wheeler Stefano Del Prato |
| format |
Journal article |
| container_title |
Diabetes Therapy |
| container_volume |
13 |
| container_issue |
5 |
| container_start_page |
847 |
| publishDate |
2022 |
| institution |
Swansea University |
| issn |
1869-6953 1869-6961 |
| doi_str_mv |
10.1007/s13300-022-01228-w |
| publisher |
Springer Science and Business Media LLC |
| college_str |
Faculty of Medicine, Health and Life Sciences |
| hierarchytype |
|
| hierarchy_top_id |
facultyofmedicinehealthandlifesciences |
| hierarchy_top_title |
Faculty of Medicine, Health and Life Sciences |
| hierarchy_parent_id |
facultyofmedicinehealthandlifesciences |
| hierarchy_parent_title |
Faculty of Medicine, Health and Life Sciences |
| department_str |
Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine |
| document_store_str |
1 |
| active_str |
0 |
| description |
Over recent years, the expanding evidence base for sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapies has revealed benefits beyond their glucose-lowering efficacy in the treatment of Type 2 diabetes mellitus (T2DM), resulting in their recognition as cardiorenal medicines. While SGLT2is continue to be recommended among the second-line therapies for the treatment of hyperglycaemia, their true value now extends to the prevention of debilitating and costly cardiovascular and renal events for high-risk individuals, with particular benefit shown in reducing major adverse cardiac events and heart failure (HF) and slowing the progression of chronic kidney disease. However, SGLT2i usage is still suboptimal among groups considered to be at greatest risk of cardiorenal complications. The ongoing coronavirus disease 2019 (COVID-19) pandemic has intensified financial pressures on healthcare systems, which may hamper further investment in newer effective medicines. Emerging evidence indicates that glycaemic control should be prioritised for people with T2DM in the era of COVID-19 and practical advice on the use of T2DM medications during periods of acute illness remains important, particularly for healthcare professionals working in primary care who face multiple competing priorities. This article provides the latest update from the Improving Diabetes Steering Committee, including perspectives on the value of SGLT2is as cost-effective therapies within the T2DM treatment paradigm, with particular focus on the latest published evidence relating to the prevention or slowing of cardiorenal complications. The implications for ongoing and future approaches to diabetes care are considered in the light of the continuing coronavirus pandemic, and relevant aspects of international treatment guidelines are highlighted with practical advice on the appropriate use of SGLT2is in commonly occurring T2DM clinical scenarios. The ‘SGLT2i Prescribing Tool for T2DM Management’, previously published by the Steering Committee, has been updated to reflect the latest evidence and is provided in the Supplementary Materials to help support clinicians delivering T2DM care. |
| published_date |
2022-05-01T04:17:11Z |
| _version_ |
1763754148601266176 |
| score |
11.012678 |